Skip to main content

Tumor Infiltrating Myeloid Cell Compartment

Objective

The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally contribute to cancer development. However, the mechanisms underlying pro- versus anti-tumor programming of neoplastic tissues by these immune cells remain obscure.
The ITN TIMCC aims to improve anti-tumor therapy by defining general and tumor type specific molecular and cellular immunological pathways (e.g signal transduction and downstream effector pathways) in tumor development and during therapeutic intervention based on an extensive analysis of the infiltrating myeloid cell compartment in human tumor biopsies using a large variety of techniques and functional analysis of the corresponding models of a variety of human tumors, affecting different organs, in a unique cohort of genetically modified mice treated with different types of anti-tumor therapy.
The program will train the appointed researchers in a variety of methodology and technology from genomic technologies and bioinformatics via genetically modified mice to the design and application of therapeutic strategies to understand and manipulate the many interactions of the myeloid cell compartment with developing tumors. By defining underlying molecular and cellular pathways new targets will be identified to be explored by the participating SMEs. The program will deliver young researchers equipped with a broad knowledge in immunology, genetics and oncology and insight in the complexity of translational medicine therefore better prepared to meet new challenges in the field.

Call for proposal

FP7-PEOPLE-2012-ITN
See other projects for this call

Coordinator

ACADEMISCH ZIEKENHUIS LEIDEN - LEIDS UNIVERSITAIR MEDISCH CENTRUM
Address
Albinusdreef 2
2333 ZA Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 870 434,20
Administrative Contact
Ruud Esveld (Mr.)

Participants (7)

RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN
Germany
EU contribution
€ 447 437,76
Address
Regina Pacis Weg 3
53113 Bonn
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Daniela Hasenpusch (Ms.)
QUEEN MARY UNIVERSITY OF LONDON
United Kingdom
EU contribution
€ 573 413,28
Address
327 Mile End Road
E1 4NS London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Thorsten Hagemann (Dr.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 523 150,32
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pirkko Boox (Mrs.)
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 477 022,92
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
Administrative Contact
Henri Van Luenen (Dr.)
TECHNISCHE UNIVERSITAET DRESDEN
Germany
EU contribution
€ 447 437,76
Address
Helmholtzstrasse 10
01069 Dresden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Brenner (Mrs.)
ALLIGATOR BIOSCIENCE AB
Sweden
EU contribution
€ 226 772,04
Address
Scheelevagen 19A
22370 Lund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jennifer Glennon (Mrs.)
SYNOVO GMBH
Germany
EU contribution
€ 190 800,72
Address
Paul Ehrlich Str 15
72076 Tuebingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Burnet (Dr.)